Statin Use Measures



At Wellcare, we value everything you do to deliver quality care to our members – your patients. We appreciate your commitment to their positive healthcare experience.

Quality Measures

Below are two examples of Centers for Medicare & Medicaid Services (CMS) Star Ratings, which use statin therapy to evaluate health plans.

Quality Measure	Description
Statin Use in Persons with Diabetes (SUPD)	Percentage of patients ages 40-75 years with at least two diabetes medications dispensed who also received a statin medication fill during the year.
SUPD Exclusions*	Patients enrolled in hospice or with a diagnosis of end-stage renal disease (ESRD), rhabdomyolysis, myopathy, pregnancy, lactating, fertility, cirrhosis, pre-diabetes, and/or polycystic ovary syndrome.
Statin Therapy for Patients with Cardiovascular Disease	Percentage of males ages 21-75 years and females ages 40-75 years who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and received at least one high- or moderate-intensity statin medication during the year.
SPC Exclusions*	Members enrolled in hospice or with a diagnosis of ESRD, rhabdomyolysis, myopathy, pregnancy, in vitro fertilization, and/or cirrhosis. Also, members 66 years old as of Dec. 31 of calendar year with frailty and/or advanced illness.

^{*}Not an all-inclusive list

(continued)

For more than 20 years, Wellcare has offered a range of Medicare products, which offer affordable coverage beyond Original Medicare. Beginning Jan. 1, 2022, our affiliated Medicare product brands, including Allwell, Health Net, Fidelis Care, Trillium Advantage, 'Ohana Health Plan, and TexanPlus transitioned to the newly refreshed Wellcare brand. If you have any questions, please contact Provider Relations.



By Allwell
By Fidelis Care
By Health Net
By 'Ohana Health Plan
By Trillium Advantage

Action

For your convenience, we have listed high- and moderate-intensity statin medications. Please visit **www.wellcare.com** to see a list of covered statins under your patient's plan.

High-Intensity*	Moderate-Intensity*		
atorvastatin 40, 80 mg	lovastatin 40 mg	simvastatin 20, 40 mg	rosuvastatin 5, 10 mg
rosuvastatin 20, 40 mg	pravastatin 40, 80 mg	atorvastatin 10, 20 mg	

^{*}Not an all-inclusive list

Rationale

The rationale behind these recommendations is to promote ASCVD primary and secondary prevention in high-risk populations, such as patients with diabetes.

American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Management of Blood Cholesterol			
Patient Risk Category	ACC/AHA Recommendation		
Patients 40-75 years of age with diabetes and LDL-C ≥70 mg/dL	A moderate-intensity statin		
Patients 40-75 years of age without diabetes with LDL-C ≥70 mg/dL and ASCVD risk ≥7.5%	A moderate-intensity statin		
Patients with severe hypercholesterolemia (LDL-C level ≥190 mg/dL)	A high intensity statin		
Patients with established clinical ASCVD	A high intensity statin		

We recognize that you are best qualified to evaluate the potential risks versus benefits in choosing the most appropriate medications for your patients.

Reference

